BCRX logo

BCRX
Biocryst Pharmaceuticals Inc.

36,613
Mkt Cap
$1.63B
Volume
3.29M
52W High
$11.31
52W Low
$6.00
PE Ratio
-139.11
BCRX Fundamentals
Price
$6.58
Prev Close
$6.67
Open
$6.61
50D MA
$7.25
Beta
0.97
Avg. Volume
3.73M
EPS (Annual)
-$0.43
P/B
-3.57
Rev/Employee
$777,089.66
Loading...
Loading...
News
all
press releases
Royal Bank Of Canada Lowers BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00
Royal Bank Of Canada cut their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating for the company in a research note on Friday...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·1d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 5.3% - Still a Buy?
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 5.3% - Should You Buy...
MarketBeat·8d ago
News Placeholder
Campbell & CO Investment Adviser LLC Decreases Position in BioCryst Pharmaceuticals, Inc. $BCRX
Campbell & CO Investment Adviser LLC lessened its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 73.4% during the 3rd quarter, according to the company in its...
MarketBeat·11d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.8% - What's Next?
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.8% - Here's Why...
MarketBeat·15d ago
News Placeholder
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference
BioCryst Pharmaceuticals (NASDAQ:BCRX) outlined a multi-pronged growth strategy at the JPMorgan Healthcare Conference, highlighting continued momentum for its hereditary angioedema (HAE) franchise, a...
MarketBeat·19d ago
News Placeholder
Rice Hall James & Associates LLC Sells 179,891 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
Rice Hall James & Associates LLC trimmed its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 8.7% in the third quarter, according to the company in its most recent...
MarketBeat·1mo ago
News Placeholder
Alane Barnes Sells 21,773 Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 21,773 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price...
MarketBeat·1mo ago
News Placeholder
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
Assenagon Asset Management S.A. reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 14.6% during the 3rd quarter, according to its most recent filing with the...
MarketBeat·1mo ago
News Placeholder
Q4 Earnings Estimate for BCRX Issued By HC Wainwright
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a report issued on...
MarketBeat·2mo ago
<
1
2
...
>

Latest BCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.